aiwiki.page
English
Science / Biology / pd-one

PD-1

PD-1 is an inhibitory immune receptor that limits lymphocyte activation, maintains immune tolerance, and serves as a major target of cancer immunotherapy.

44 keywords8 linked from5 not yet writtenWritten by AI
ProteinGeneT CellB CellImmune Checkpoin…Peripheral Immun…ApoptosisCTLA-4PD-1

PD-1, or programmed cell death protein 1, is a cell-surface protein that restrains immune responses. Encoded in humans by the PDCD1 gene, it is expressed principally by activated immune cells, including T cells and B cells. Engagement of PD-1 by either of its two ligands, PD-L1 and PD-L2, reduces signals that would otherwise promote immune-cell activation, proliferation, and effector activity. It is therefore an important immune checkpoint: a regulatory mechanism that helps control the intensity, duration, and location of immune responses.

PD-1 protects tissues from excessive immune-mediated injury and helps maintain peripheral immune tolerance. The same inhibitory pathway can, however, limit protective responses during persistent infections and allow cancers to evade immune destruction. Antibodies that block PD-1 or its ligands have consequently become major treatments for several cancers. Their effectiveness, and their capacity to provoke inflammatory injury in normal organs, demonstrate the pathway’s central role in balancing immune protection against tissue damage.

Despite its name, PD-1 is not a conventional death receptor and does not simply instruct a cell to undergo apoptosis. Its functions depend on the cell expressing it, the availability and arrangement of its ligands, accompanying activation signals, and the history of antigen exposure.

Discovery and development of the checkpoint concept

PD-1 was identified in 1992 by Yasumasa Ishida and colleagues in Tasuku Honjo’s laboratory at Kyoto University. The investigators isolated a gene whose expression increased in experimental cell systems undergoing programmed cell death. They named it programmed cell death 1, or Pdcd1. This discovery established the molecule’s name but did not demonstrate that its physiological function was to trigger cell death. Subsequent work instead revealed a receptor involved in regulating immune activation.

A decisive advance came from mice in which Pdcd1 had been disrupted. These animals developed immune abnormalities whose form depended strongly on their genetic background. On a C57BL/6 background, aging PD-1-deficient mice developed lupus-like features, including inflammatory kidney disease and arthritis. On a BALB/c background, deficiency could produce autoimmune dilated cardiomyopathy. Such differences showed both that PD-1 restrains self-reactive responses and that the outcome of losing this restraint depends on other inherited factors. The findings also distinguished PD-1 from molecules essential for the initial development of lymphocytes: mice lacking PD-1 could generate immune cells but failed to regulate some of their subsequent activities appropriately.

Identification of the ligands clarified how this regulation operated. In 2000, Gordon Freeman and colleagues reported that PD-L1, also called B7-H1, could bind PD-1 and inhibit lymphocyte activation. PD-L2, also known as B7-DC, was identified as a second ligand in 2001. Their expression on antigen-presenting cells and, especially for PD-L1, on many nonimmune tissues provided a mechanism by which both immune cells and surrounding tissues could influence ongoing responses. Work by Lieping Chen and colleagues had independently helped establish B7-H1 biology and subsequently connected its expression on tumors with immune escape.

Cancer experiments then transformed the pathway from an explanation of immune regulation into a therapeutic target. Studies published in 2002 showed that PD-L1 expression could help tumors resist T-cell attack and that interrupting the pathway could enhance antitumor immunity in experimental models. These findings complemented research on CTLA-4, another inhibitory receptor, while revealing a checkpoint with a different distribution and pattern of action. Clinical development accelerated during the following decade, leading to the first approvals of PD-1-blocking antibodies in 2014. The 2018 Nobel Prize in Physiology or Medicine was awarded jointly to James P. Allison and Tasuku Honjo “for their discovery of cancer therapy by inhibition of negative immune regulation,” recognizing the therapeutic consequences of research on CTLA-4 and PD-1.

Gene, protein architecture, and molecular recognition

The human PDCD1 gene lies on chromosome 2 at 2q37.3. Its canonical protein product contains 288 amino acids and belongs to the immunoglobulin superfamily. PD-1 is a type I transmembrane glycoprotein: its amino-terminal region projects outside the cell, a single membrane-spanning segment anchors it in the cell membrane, and its carboxy-terminal tail extends into the cytoplasm. This arrangement allows ligand binding outside the cell to influence signaling machinery inside it without PD-1 itself crossing the membrane or entering the nucleus.

The extracellular portion contains one immunoglobulin variable-like domain. This compact, β-sheet-rich structure forms the ligand-binding surface. Although PD-1 is often discussed alongside the CD28 and CTLA-4 receptor family, its architecture is not identical to theirs. PD-1 is generally regarded as monomeric, whereas CD28 and CTLA-4 form disulfide-linked dimers. This distinction matters because receptor geometry influences how binding partners are arranged where two cells contact one another. Structural studies using X-ray crystallography have defined overlapping surfaces through which PD-L1 and PD-L2 engage PD-1, explaining why occupancy by a blocking antibody can prevent ligand access.

The cytoplasmic tail has no intrinsic enzymatic activity. Instead, it contains two tyrosine-based signaling motifs: an immunoreceptor tyrosine-based inhibitory motif, or ITIM, and an immunoreceptor tyrosine-based switch motif, or ITSM. After their tyrosines are phosphorylated, these motifs provide docking sites for intracellular signaling proteins. The ITSM has a particularly important role in recruiting inhibitory phosphatases. Thus, PD-1 functions as a regulated scaffold rather than as a self-contained enzyme: its effects require appropriate activation of neighboring signaling components and access to substrates that can be dephosphorylated.

PD-1 is also modified after its initial synthesis. N-linked glycosylation of the extracellular domain influences folding, surface stability, and recognition by some antibodies. Consequently, measurements made with purified receptor fragments do not capture every feature of PD-1 on living cells. Alternative splicing can generate additional transcripts, including forms predicted to lack the transmembrane region; soluble PD-1 has also been investigated in biological fluids. Such forms should not be treated as interchangeable with the canonical membrane receptor. Their abundance, origin, binding activity, and clinical significance require separate experimental assessment. The therapeutically established target is chiefly the cell-surface receptor that participates in contacts between immune cells and ligand-bearing cells.

PD-L1, PD-L2, and the geography of inhibition

PD-1 recognizes two principal ligands: PD-L1, encoded by CD274, and PD-L2, encoded by PDCD1LG2. Both are transmembrane members of the B7 family and contain extracellular immunoglobulin-like domains. Their distributions differ substantially. PD-L1 can be expressed by hematopoietic cells, including dendritic cells, macrophages, and activated lymphocytes, as well as by endothelial, epithelial, and other nonhematopoietic cells. PD-L2 is more restricted under many physiological conditions, with expression particularly associated with antigen-presenting cells, although it can also occur in other tissues and cancers.

Ligand availability is dynamic rather than fixed. Inflammatory signals can increase PD-L1 expression, with interferon-γ providing a particularly important stimulus. A T cell recognizing a target may release interferon-γ, causing nearby cells to increase PD-L1 and thereby create a local negative-feedback circuit. PD-L2 is regulated differently; interleukin-4 and related immune programs can promote its expression on certain antigen-presenting cells. PD-L2 generally binds PD-1 more tightly than PD-L1 in purified-protein assays, but binding affinity alone does not determine physiological importance. The number of ligand molecules, their accessibility, the cell types involved, and the duration of contact also influence signaling.

The spatial arrangement of these molecules is consequential. PD-1 can interact with a ligand on an opposing cell, a configuration termed trans binding. At a T-cell contact site, this places inhibitory signaling close to receptors transmitting antigen and costimulatory signals. Ligands may also participate in interactions within the same membrane. PD-L1 can bind CD80 in cis, altering its availability for PD-1 and affecting the wider network involving CD80, CD28, and CTLA-4. PD-L2 has another binding partner, repulsive guidance molecule b, or RGMb, whose functions are not identical to those of PD-1. These interactions mean that manipulating one component can have consequences beyond a simple two-molecule receptor–ligand model.

This network helps explain why drugs targeting PD-1 and drugs targeting PD-L1 are related but not mechanistically identical. Blocking PD-1 generally prevents inhibitory engagement by both PD-L1 and PD-L2. Blocking PD-L1 leaves PD-1–PD-L2 interaction available and can affect PD-L1’s interactions with other partners, depending on the antibody. These distinctions do not establish that one drug class is universally more effective or safer. Clinical outcomes also depend on antibody properties, cancer type, treatment combination, and patient population. They do, however, establish why “PD-1 blockade” and “PD-L1 blockade” should not be used as exact molecular synonyms.

Intracellular signaling and control of T-cell activation

A T cell normally integrates several inputs before mounting an effective response. The T-cell receptor recognizes an antigen fragment presented by a major histocompatibility complex molecule, while costimulatory receptors provide additional signals. PD-1 does not replace these recognition systems. Instead, it modifies their output when its ligand is encountered in an appropriate signaling context. Ligand binding alone is not adequately described as an autonomous “off switch”; effective inhibition depends on events such as receptor phosphorylation and colocalization with active signaling complexes.

Following activation, kinases including Lck phosphorylate tyrosines in the PD-1 cytoplasmic tail. The phosphorylated receptor recruits phosphatases, especially SHP-2, encoded by PTPN11. These enzymes remove phosphate groups from selected signaling proteins. Experimental systems have shown particularly effective inhibition of CD28-associated signaling, and biochemical reconstitution studies have identified CD28 as a preferred substrate under some conditions. PD-1 can also diminish signaling associated with the T-cell receptor. The relative importance of these targets varies with receptor abundance, contact geometry, and the experimental or physiological setting.

Downstream effects include reduced activity in pathways involving phosphoinositide 3-kinase, AKT, and RAS–MAP kinase signaling. These changes can decrease production of interleukin-2, limit cell-cycle entry, and reduce the expression or activity of molecules involved in cytotoxicity. PD-1 also influences metabolism. Activated effector T cells commonly increase glucose uptake and biosynthetic activity; PD-1 engagement can restrain aspects of this metabolic reprogramming. In some experimental settings it favors relatively greater reliance on fatty-acid oxidation. Such observations describe context-dependent shifts, not a universal metabolic state imposed on every PD-1-positive cell.

The pathway is more complex than a linear sequence of PD-1, SHP-2, and complete T-cell shutdown. SHP-1 can participate in some settings, and genetic experiments have shown that removing SHP-2 does not always abolish every inhibitory effect attributed to PD-1. Other signaling networks and compensatory mechanisms can alter the outcome. Moreover, PD-1 modifies signal strength rather than necessarily eliminating all function: a cell may retain survival, migration, or some cytokine production while losing other activities. Measurements of receptor occupancy, individual phosphorylation events, proliferation, and target-cell killing therefore describe different levels of the response. A mechanistic account must distinguish these levels rather than treating any one laboratory readout as a complete measure of PD-1 activity.

Expression, immune tolerance, and tissue protection

PD-1 expression is usually low on resting naïve T cells and rises after activation. The duration and intensity of antigen exposure help determine whether expression is transient or sustained. Its transcription is controlled by several regulatory programs, including activation-dependent transcription factors and changes in chromatin accessibility. NFAT can promote PDCD1 expression, while persistent stimulation can establish a regulatory environment that supports continued receptor production. PD-1 expression therefore records aspects of a cell’s recent and longer-term history, but it does not by itself specify a single functional state.

The receptor is not confined to conventional cytotoxic T cells. It occurs on activated helper T cells, B cells, and subsets of other immune populations. Follicular helper T cells in germinal centers characteristically express high PD-1 levels, even though they perform specialized functions supporting antibody responses. PD-1 pathway interactions help regulate communication among these cells, follicular regulatory T cells, and B cells. The receptor can also be expressed by regulatory T cells, but its effects on their abundance and suppressive function vary with tissue and inflammatory context. Consequently, expression on a regulatory cell cannot automatically be interpreted as equivalent to expression on an exhausted cytotoxic T cell.

PD-1 contributes to tolerance mainly by regulating immune cells after they have developed and encountered antigen. It complements central immune tolerance, in which developing lymphocytes are screened for strong self-reactivity, rather than substituting for it. Some self-reactive lymphocytes normally escape developmental deletion. Peripheral checkpoints, limited costimulation, regulatory cells, and restricted antigen access collectively prevent these cells from damaging tissues. PD-1 raises the threshold for activation or limits the persistence of responses, especially where tissues express its ligands during inflammation.

Evidence for tissue protection comes from both animal genetics and human therapeutic blockade. The autoimmune diseases of PD-1-deficient mice demonstrate that the consequences of losing the receptor depend on genetic background and target-organ biology. In humans, inflammatory toxicities arising during checkpoint treatment show that interrupting the pathway can release responses against normal tissues. Nevertheless, ordinary tolerance is not maintained by PD-1 alone. CTLA-4, regulatory T cells, antigen availability, and numerous local signals provide overlapping controls. This redundancy explains why loss or blockade of a single checkpoint does not produce the same disease in every individual. It also explains why the physiological function of PD-1 is best understood as part of an interacting regulatory system rather than as a single mechanism separating self from nonself.

Persistent infection and T-cell exhaustion

During an acute infection, antigen-specific T cells expand, perform effector functions, and then contract as the pathogen is cleared. A subset survives as memory cells. Persistent infection presents a different problem: antigen can remain available for weeks, months, or years, continually stimulating the same populations. Under these conditions, T cells may enter states collectively described as T-cell exhaustion. These states involve altered cytokine production, proliferative capacity, metabolism, transcriptional regulation, and expression of inhibitory receptors. Sustained PD-1 expression is a prominent feature, but it is neither a sufficient definition of exhaustion nor exclusive to it.

A landmark 2006 study by Daniel Barber and colleagues showed that blocking PD-L1 in mice with chronic lymphocytic choriomeningitis virus infection could restore aspects of antiviral T-cell function and improve viral control. Studies of human chronic infections, including HIV infection, subsequently linked elevated PD-1 on virus-specific T cells with measures of dysfunction and disease activity. These observations established that inhibitory signaling can actively maintain part of the impaired response. They did not establish that checkpoint blockade reliably eliminates persistent human infections, whose biology includes viral reservoirs, tissue distribution, immune escape, and potential inflammatory damage.

Exhausted T-cell populations are heterogeneous. A progenitor-like subset often expresses the transcription factor TCF-1 and retains the capacity to proliferate and generate more differentiated descendants. Other cells have more terminally differentiated exhausted states, with a more restricted capacity for sustained expansion. PD-1 blockade commonly acts most effectively through the responsive progenitor-like compartment rather than uniformly converting every exhausted cell into a conventional effector. The term “reinvigoration” therefore describes expansion or altered activity within a structured population, not necessarily complete reversal of its developmental history.

Epigenetic studies reinforce this distinction. Exhausted cells can retain characteristic patterns of accessible chromatin after checkpoint blockade, and restored effector activity may be incomplete or temporary. Transcriptional regulators such as TOX participate in establishing or maintaining adaptations to persistent stimulation. Some of these adaptations protect cells from the consequences of unremitting activation, even as they reduce pathogen clearance. Exhaustion is therefore not simply an accidental failure of immunity. It can represent a compromise between controlling persistent antigen and limiting immunopathology. This dual role is important when interpreting experiments: increased cytokine production or reduced pathogen burden must be considered separately from tissue injury, long-term persistence of the response, and overall disease outcome.

Tumor immunity and the basis of PD-1 blockade

Cancers can generate antigens recognizable by T cells, including peptides derived from somatic mutations and, in virus-associated cancers, viral proteins. Recognition is not enough to ensure tumor elimination. The tumor microenvironment may restrict lymphocyte entry, impair antigen presentation, supply suppressive signals, or expose T cells to persistent stimulation. PD-1 signaling is one important component of this environment. Tumor-reactive T cells frequently express PD-1, while malignant cells, infiltrating myeloid cells, and surrounding stromal elements may express PD-L1 or PD-L2.

Two broad routes can increase tumor-associated PD-L1. In adaptive immune resistance, interferon-γ released by tumor-reactive lymphocytes induces PD-L1 in nearby cells. Here, inhibitory ligand expression is partly a response to an existing immune attack. In intrinsic regulation, oncogenic pathways or genetic alterations promote PD-L1 independently of an immediately adjacent T-cell response. Classical Hodgkin lymphoma provides a well-characterized example: alterations involving chromosome region 9p24.1 can increase dosage of genes encoding PD-L1 and PD-L2, and associated JAK2 signaling can further support their expression. These mechanisms can coexist within the same disease.

Blocking PD-1 interrupts inhibitory receptor engagement and can increase antitumor T-cell activity. The therapeutic antibodies do not generally act by directly poisoning malignant cells. Most established anti-PD-1 antibodies use an IgG4 framework selected in part to limit unwanted destruction of the PD-1-expressing lymphocytes they target. Effective therapy can involve proliferation of pre-existing tumor-reactive cells, recruitment or expansion of additional clones, and immune activity in tumor-draining lymph nodes as well as within the tumor itself. Thus, a biopsy captures only one location within a wider response.

The pathway’s importance varies among tumors and individuals. A malignancy may express PD-L1 yet remain resistant because it lacks recognizable antigens, excludes T cells, or has defects in antigen presentation. Conversely, a tumor classified as PD-L1-negative in one specimen may still respond because expression is heterogeneous, changes over time, or occurs on immune cells not adequately represented by the assay. PD-1 blockade is consequently not a universal release of a pre-existing, fully effective antitumor response. Its success depends on multiple biological requirements being met. Combination treatments seek to address some of these requirements—for example, by pairing checkpoint blockade with chemotherapy, radiotherapy, targeted agents, or inhibition of another checkpoint—but their mechanisms and clinical results depend on the specific disease and regimen.

Therapeutic antibodies and clinical development

The first major clinical successes of PD-1 blockade occurred in advanced melanoma and were soon followed by applications in lung cancer and other malignancies. Nivolumab received its first approval in Japan in July 2014 for unresectable melanoma. Pembrolizumab received United States approval in September 2014 for advanced melanoma in a specified previously treated population, and nivolumab received a United States melanoma approval that December. These early authorizations were followed by a large program of randomized trials establishing disease-specific uses and comparisons with existing treatments.

Non-small-cell lung cancer provided important evidence that benefit extended beyond melanoma. In the phase III CheckMate 017 trial in previously treated squamous non-small-cell lung cancer, median overall survival was 9.2 months with nivolumab and 6.0 months with docetaxel. CheckMate 057, conducted in previously treated nonsquamous disease, reported median overall survival of 12.2 months and 9.4 months, respectively. These results helped establish immune checkpoint inhibition as a treatment capable of improving survival in common solid tumors. Later studies evaluated first-line use, combinations, and treatment around surgery, rather than limiting the approach to patients whose previous therapies had failed.

Pembrolizumab’s KEYNOTE-024 trial examined previously untreated advanced non-small-cell lung cancer with PD-L1 expression on at least 50% of tumor cells and without sensitizing EGFR mutations or ALK rearrangements. The initial report found median progression-free survival of 10.3 months with pembrolizumab versus 6.0 months with platinum-based chemotherapy. Such eligibility details are integral to interpreting a trial: a result in a biomarker-selected population cannot automatically be applied to every patient with the same broad cancer diagnosis. Likewise, trial-specific dosing, comparators, subsequent treatments, and follow-up affect the meaning of survival estimates.

In 2017, the United States Food and Drug Administration granted pembrolizumab a tissue-agnostic indication for certain previously treated unresectable or metastatic solid tumors with high microsatellite instability or deficient mismatch repair. This marked a shift toward selecting some treatments by a shared molecular feature rather than solely by the organ in which the cancer arose. Other established PD-1 antibodies include cemiplimab, with approvals in diseases including advanced cutaneous squamous-cell carcinoma. Uses now span several solid tumors and hematologic malignancies, but they remain specific to drug, jurisdiction, disease setting, and combination. A class-level statement that PD-1 inhibition can treat cancer is therefore less precise than the evidence required for any particular clinical indication.

Biomarkers, resistance, and response assessment

PD-L1 immunohistochemistry is among the most widely used biomarkers for checkpoint therapy, but it is not one uniform test. Some assays measure the tumor proportion score, the percentage of viable tumor cells showing defined membrane staining. Others use a combined positive score that incorporates staining in selected tumor-associated immune cells relative to the number of viable tumor cells. Antibody clone, staining platform, scoring rules, threshold, cancer type, and treatment regimen all matter. A cutoff validated for one indication is not automatically valid in another, and a small biopsy may not represent the full spatial distribution of expression.

Deficient DNA mismatch repair and microsatellite instability identify another important biological context. Mismatch-repair defects can allow insertions and deletions to accumulate in repetitive DNA, generating altered coding sequences and potentially immunogenic peptides. High tumor mutational burden can also correlate with response in some settings, but the relationship is imperfect. Mutation count does not directly measure whether mutations produce expressed, presented, and recognizable antigens. Sequencing method, genomic territory sampled, tumor type, and threshold affect the result. No single widely used biomarker captures all of the steps required for a productive antitumor immune response.

Resistance is commonly divided into primary resistance, in which meaningful benefit does not occur initially, and acquired resistance, in which a tumor progresses after an initial response. Potential mechanisms include loss of antigen presentation through disruption of β2-microglobulin or major histocompatibility complex expression; defects in interferon signaling involving proteins such as JAK1 or JAK2; changes in tumor antigens; and immune exclusion associated with stromal or oncogenic programs. Additional inhibitory receptors and suppressive myeloid populations can also contribute. Particular mechanisms have been demonstrated in defined tumors, but they should not be assumed to explain every resistant case.

Response assessment introduces a separate challenge. Checkpoint treatment can produce durable tumor regression, but inflammatory infiltration or the appearance of additional lesions can occasionally precede later improvement. This pattern is termed pseudoprogression and occurs in a minority of cases; most unequivocal progression is not pseudoprogression. Immune-modified assessment systems such as iRECIST were developed to standardize data collection in trials when apparent progression requires confirmation. Reports have also described unusually rapid tumor growth after checkpoint treatment, often termed hyperprogression. Definitions vary, and separating a treatment-associated effect from naturally aggressive disease and pre-treatment growth patterns remains difficult. These assessment problems underline the distinction between a radiological pattern, a biological mechanism, and a demonstrated effect of treatment.

Immune-related toxicity and research beyond cancer

The adverse effects most characteristic of PD-1 and PD-L1 blockade arise from altered immune regulation rather than the nonspecific injury typical of many cytotoxic drugs. Immune-related adverse events can involve the skin, bowel, liver, lungs, endocrine glands, kidneys, heart, nervous system, and other organs. Examples include inflammatory dermatitis, colitis, hepatitis, pneumonitis, thyroid dysfunction, hypophysitis, and insulin-deficient diabetes. Myocarditis and some neurological syndromes are uncommon but can be severe. Frequency and severity depend on the drug regimen, cancer population, definitions used, and whether another immunotherapy is given concurrently.

These events do not all share a single mechanism. Proposed and documented contributors include activation of autoreactive T cells, recognition of antigens shared between tumor and normal tissue, changes in autoantibody activity, and disruption of organ-specific immune regulation. Endocrine inflammation may destroy hormone-producing cells, so resolution of the inflammatory episode does not necessarily restore the lost function. Events can occur during treatment and sometimes after treatment has ended. Their timing and organ distribution differ from those of many conventional anticancer agents, and the absence of early toxicity does not imply that later immune effects cannot occur.

Combining PD-1 inhibition with CTLA-4 blockade can improve antitumor outcomes in selected settings but also increases the frequency of serious immune toxicity compared with PD-1 blockade alone. Checkpoint treatment in people with pre-existing autoimmune disease or transplanted organs presents additional biological issues because the same regulatory pathways may help restrain autoimmunity or protect an allograft. These observations are especially direct evidence that therapeutic checkpoint inhibition affects systemic tolerance, not just the tumor. An adverse immune event is not, by itself, proof that treatment is controlling the cancer, and antitumor benefit can occur without such toxicity.

Research beyond cancer explores the opposite therapeutic direction: strengthening PD-1-mediated inhibition rather than blocking it. Agonistic antibodies and other approaches are being investigated for autoimmune and inflammatory diseases. Their design is challenging because inhibitory signaling depends on receptor arrangement and proximity to active signaling complexes; merely binding PD-1 does not ensure productive agonism. Studies in persistent infections likewise examine whether limited checkpoint modulation can enhance protective immunity without causing excessive tissue injury. Across these settings, a central experimental task is to identify which cells must be modulated, where the relevant receptor–ligand contacts occur, and whether altered activity persists after intervention. Single-cell profiling, spatial analysis, and measurements of antigen-specific lymphocyte populations are helping distinguish these possibilities without assuming that every PD-1-positive cell has the same function or therapeutic relevance.